On February 29th, 2024, Shanghai, Innolake Biopharm announced China NMPA has received its IND application for B7H3 ADC with Eribulin as payload (ILB-3101), indicating that ILB-3101 as Innolake leading ADC program will enter the important stage of clinical development very soon. Innolake will also present ILB-3101 program preclinical evaluation data as poster format at AACR Annual Meeting 2024 in San Diego, California.

The poster information of B7H3 ADC(ILB-3101) as below:

Title: ILB-3101, a novel B7H3-targeting ADC with Eribulin as payload, demonstrates strong tumor killing activities and favorable PK/TOX profile in preclinical evaluation

Date and Time: Tuesday Apr 9, 2024 9:00 AM - 12:30 PM

Location: Poster Section 42

Poster Board Number: 9

Published Abstract Number: 5087

ILB-3101 B7H3 ADC

B7H3, a B7 family member of immune checkpoint proteins, is overexpressed in a broad spectrum of malignant tumors. It has become an attractive target for cancer therapies in recent years. ILB-3101, a potential best-in-class ADC, was constructed by conjugating a potent mitotic inhibitor Eribulin to a proprietary anti-B7H3 mAb through a proprietary linker. This ADC molecule has been developed and preclinically evaluated as both the potentially 1st line ADC treatment for patients with B7H3 expressed in Eribulin sensitive cancer types and the later line ADC treatment for patients whose cancer are B7H3 positive but TopoI inhibitor resistant.